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Abstract:  A  prospective  pragmatic  interventional  study  was  conducted  to  evaluate  the 
effectiveness of varenicline for smoking cessation among a cohort of motivated smokers 
attending  two  smoking  cessation  clinics.  Smokers  between  18  and  65  years  who  had 
smoked 10 or more cigarettes per day were included. All participants received cognitive-
behavioural  varenicline  according  to  approved  dose  and  prescriptions.  Continuous 
abstinence, validated by exhaled CO levels, was assessed in each control. A total of 264 
smokers – 155 males (58.7%) and 109 females (41.3%) – were included. Mean age was 
43.7, amount smoked was 23 cigarettes per day and 61.4% had at least one prior attempt to 
quit. The continuous abstinence rate at end of treatment (12 wks) was 58.3%. Conclusions: 
varenicline and cognitive-behavioural intervention are effective for smoking cessation with 
high continuous abstinence rates when are used in a clinical setting. 
Keywords:  Smoking  cessation;  varenicline;  cognitive-behavioural  intervention; 
continuous abstinence. 
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1. Introduction 
 
Cigarette  smoking  continues  to  be  the  major  cause  of  morbidity  and  mortality  in  Western 
populations. Several studies [1,2] reported that 60-70 percent of smokers want to quit and intend to 
stop,  but  only  3-5%  of  them  remain  abstinent  for  a  year  [3].  Smoking  is  a  complex  behaviour 
influenced by both genetic and environmental factors [4,5]. Nicotine is the component of tobacco that 
is responsible for reward, reinforcement and the withdrawal effects of cigarettes [5]. When a smoker 
inhales cigarette smoke, nicotine diffuses rapidly into the brain where it binds to nicotinic cholinergic 
receptors (nAChRs). One physiological effect of nAChR activation is dopamine release in the nucleo 
acumbens, an important focus for the reward properties of nicotine [6]. 
Currently  available  first  line  smoking  cessation  therapies  include  nicotine  replacement  therapy, 
bupropion and, most recently, varenicline. Nicotine replacement therapy acts on nAChRs to replace the 
effects of nicotine from tobacco and the principal action is the relief of withdrawal symptoms and, a 
second mechanism, is positive reinforcement, particularly, for the arousal and stress relieving effects 
[6]. The precise mechanism of bupropion for smoking cessation is unclear; however its effects may be 
related to reduced cravings and withdrawal symptoms and, on the other hand, prevention of dopamine 
reuptake [7]. 
Varenicline, licensed by the European Agency for the Evaluation of Medical Products in September 
2006 and introduced for clinical use in Spain in January 2007, is a selective 42 nAChR partial 
agonist  developed  for  smoking  cessation.  The  agonist  activity  reduces  craving  and  withdrawal 
symptoms and their antagonist properties, on the other hand, it reduces the reward experienced by 
those who relapse during treatment increasing the abstinence rates [8,9]. Several randomized, double-
blind placebo controlled trials [10-14] had reported significantly higher abstinence rates by varenicline 
compared  to  bupropion,  NRT  and placebo. These clinical  trials provide scientific evidence  of the 
efficacy and safety of varenicline used as smoking cessation therapy however; the final evaluation of 
clinical  effectiveness  is  when  varenicline  is  used  in  real-life  settings  and  no  studies  have  been 
published that report data on predictors of success when varenicline is used for smoking in such a real-
world setting.  
The  aim  of  this  study  was  to  assess  the  effectiveness  of  varenicline  and  cognitive-behavioural 
intervention when both are used under real clinical practice conditions during a 12 weeks period of 
treatment  and  investigated  the  role  of  different  factors  as  predictors  of  abstinence  at  the  end  of 
treatment with varenicline. 
 
2. Methods  
 
2.1. Study Design 
 
A prospective pragmatic interventional study was carried out among motivated to quit smokers 
attending two smoking cessation clinics in Barcelona, Spain as routine cases between January and July 
2007. The study protocol was approved by the ethical review committee of our institution.  Int. J. Environ. Res. Public Health 2009, 6                 
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2.2. Participants 
 
Participants were chain smokers motivated to quit and attending two specialist’s smoking cessation 
clinics during the study period. Smokers between the ages of 18 and 65 years and who had smoked an 
average of 10 or more cigarettes per day during the previous month were included in the study. Twenty 
eight  smokers  (9.0%)  with  current  depressive  disorder,  a  previous  psychosis  or  bipolar  disorder, 
pregnancy or breastfeeding were excluded from the study. Psychiatric comorbidity was assessed using 
BDI  inventory  and  brief  psychiatric  rating  scale.  Thirty  percent  of  smokers  (29.9%)  had  a  major 
chronic  associated  disease  including  cardiovascular  disease,  diabetes,  chronic  bronchitis  
and asthma.  
 
2.3. Intervention  
 
All smokers received a standardized program for smoking cessation including pharmacological and 
cognitive-behavioural  interventions  (developing  a  specific  action  plan  and  alternative  behaviours). 
Subjects  received  five  20-30  minute  individual  consultations  during  the  treatment  period  and 
varenicline was prescribed according to indications, 0.5 mg/day for 3 days, 0.5 mg twice daily and 1 
mg twice daily for 11 weeks. The pharmacologic treatment begins always one week before the target 
quit day. Smokers attended follow-up control visits at weeks 2,4,6,8 and 12 after quit day. 
 
2.4. Assessments 
 
At baseline a detailed smoking history, health data and participant’s motivation, using Richmond 
test, was gathered. Questionnaires included questions as sex, age, when cigarette use started, number of 
cigarettes per day and Fagerströ m test for nicotine dependence (FNTD), previous attempts to quit, 
presence of other smokers in the household and former and current diseases and medications. Self-
reported cigarette consumption, exhaled CO level, weight and possible adverse effects were measured 
at  all  follow-up  visits.  Adverse  event  were  assessed  systematically  in  each  control  using  a  
structured questionnaire. Effectiveness was measured as continuous abstinence rate (CAR) confirmed 
by exhaled CO levels of 10 ppm or below from week 2 through week 12. On the other hand, point 
prevalence of abstinence was defined as no smoking in the previous seven days as verified by an 
expired level of CO lower than 10 ppm. 
 
2.5. Statistical Analysis  
 
Data  were  first  entered  into  a  relational  database  (Access  2000,  Microsoft  Corp,  Redmond, 
Washington) and the converted into a SPSS file (SPSS 12.0, Chicago, Illinois). In the descriptive 
analysis, categorical variables are expressed as proportions and continuous variables as mean (standard 
deviation). Univariate analysis of variables from the entire population was performed using chi square 
test and two-sample test for continuous data. All test using a significant level of 0.05.  Int. J. Environ. Res. Public Health 2009, 6                 
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Multivariate logistic regression was used to identify independent predictors (age, gender, number of 
cigarettes per day, number of attempts, FTND score and associated disease) associated with continuous 
abstinence at week 12 as primary outcome. Models were fitted including all variables associated with 
the outcome. Any variable was subsequently eliminated from the model if the chi-square statistic of 
likelihood  ratio  test  indicated  no  statistical  significance.  No  substantial  confounding of odds  ratio 
estimates for the other variables were observed. Possible effect modification was analyzed by fitting 
interaction  terms  between  variables  and  resulting  models  were  compared  by  likelihood  ratio  test. 
Results are showed as crude and adjusted odds ratios and their 95% confidence intervals. Subjects who 
did not attend follow-up visits were considered smokers. 
 
3. Results 
 
Baseline information and demographic characteristics of the participants are reported in Table 1. Of 
the 264 included smokers, 155 (58.7%) were males and 109 (41.3%) females, with an average age of 
43.7 years who smoked an average of 23 cigarettes per day and 61.4% had at least one prior quit 
attempt. Forty percent of smokers indicated other smokers in the household and 29.9% of included 
subjects had an associated disease. The drop-out rate of consultation attending was 37.8% (n = 71) 
without statistical differences by sex and age (p > 0.05). 
 
Table 1. Demographic and baseline characteristics of included smokers by gender. 
  Male 
N = 155 
Female 
N = 109 
Total 
N = 264 
p value 
Age mean (SD)  45.9 (10.4)  39.5 (7.9)  43.7 (10.1)  < 0.001* 
Cig/day. Mean (Range)  28 (15-50)  22 (10-40)  23 (10-50)  0.008* 
Nº  previous attempts. Mean (SD)  1.6 (1.0)  1.4 (1.3)  1.5 (1.1)  0.6* 
Age starting smoking. Mean (SD)  17.1 (5.0)  17.5 (3.4)  17.3 (4.5)  0.9* 
Fagerströ m test score. Mean (SD)  6.4 (2.5)  6.0 (2.6)  6.3 (2.5)  0.4* 
Longest  previous  abstinence 
(days) Mean (Range) 
6.2 (0-60)  7.3 (0-100)  6.5 (0-100)  0.7* 
* p value for T-test. 
After 12 weeks of follow-up, 154 of the 264 smokers were sustained abstainers post quit-day with 
an overall success rate of 58.3% (Table 2). When differences of continuous abstinence were assessed 
by gender, males and females showed similar rates after 4 and 6 weeks of follow-up (Table 2). At week 
12,  female  continuous  abstinence  rate  (61.5%)  was  higher  than  for  males  (56.1%),  although  the 
difference was not statistically significant (OR 0.91; p 0.06). Int. J. Environ. Res. Public Health 2009, 6                 
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Table 2. Continuous abstinence rate by gender. 
 
wks 2-4 
CAR (n/N) 
wks 2-6 
CAR (n/N) 
wks 2-12 
CAR (n/N) 
Males  79.3% (123/155)  67.1% (104/155)  56.1% (87/155) 
Females  77.9% ( 85/109)  66.0% ( 72/109)  page 6 second parag. 
Total  78.8% (208/264)  66.7% (176/264)  58.3% (154/264) 
CAR: Continuous abstinence rate. 
 
The  continuous  abstinence  rate  for  the  last  four  weeks  of  treatment  (weeks  9-12)  was  61.3% 
(162/264). When the successful-12 week predictors were assessed in a univariate model (Table 3), the 
number of cigarettes consumed per day, and FTND score, were clear predictors of abstinence at the end 
of treatment (OR 0.58, 95% CI 0.2-0.7 and OR 0.71, 95% CI 0.7-0.9, respectively). On the other hand, 
number of previous attempts (OR 0.79, 95% CI 0.2-1.0) and presence of other smoker in the household 
(OR 0.59, 95% CI 0.2-0.9) were also associated with continuous abstinence at 12 week (Table 3). The 
effect of associated disease was not significant (Table 3). 
Table 3. Estimated crude Odds Ratios for variables associated with continuous abstinence. 
 
 
Abstainers at 
week 12 
(Quitters/Total) 
Crude OR for 
abstinence 
at week 12 
(95% CI**) 
Adjusted OR* for 
abstinence 
at week 12 
(95% CI**) 
Associated Disease 
 None  
 Yes 
 
114/185 
40/ 79 
 
1.0 
1.21 (0.81-1.93) 
 
Cig/day 
 > 30 
 21-30 
  20 
 
 
25/ 68 
41/ 58 
88/138 
 
1.0 
0.52 (0.16-0.60) 
0.58 (0.20-0.78) 
 
1.0 
0.46 (0.10-0.68) 
0.50 (0.16-0.80) 
p for trend 0.02 
Previous attempts 
 0 
 >= 1 
 
 51/102 
103/162 
 
1.0 
0.79 (0.25-1.00) 
 
1.0 
0.67 (0.22-0.96) 
FTND score 
 > 6 
 3-6 
 < 3 
 
70/ 136 
49/ 80 
35/ 48 
 
1.0 
0.84 (0.47-1.97) 
0.71 (0.17-0.90) 
 
1.0 
0.74 (0.38-2.0) 
0.80 (0.51-1.8) 
p for trend 0.4 Int. J. Environ. Res. Public Health 2009, 6                 
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Table 3. Cont.  
Other smoker in 
household 
 Yes 
 Non 
 
 
 43/105 
111/159 
 
 
1.0 
0.59 (0.25-0.98) 
 
 
1.0 
0.50 (0.21-0.87) 
OR : Odds Ratio; * Adjusted Odds Ratios by age, gender, center and all variable in the 
table; ** 95% CI : 95% confidence intervals. 
 
When all significant predictor factors were included in a multivariate model (Table 3), estimated 
OR adjusted by age, gender, clinic and all variable in the table, nothing changed significantly. Smoking 
less than 30 cigarettes per day, one or more previous attempts and no presence of other smokers in the 
household persisted as significant predictors of smoking cessation after 12 weeks of treatment.  
Finally, 39.1% (103/264) of all smokers showed any adverse event observed mostly during the first 
six weeks of treatment. Insomnia was the most frequent side effect with 31.1% of smokers. Nausea 
occurred in 29 smokers (28.7%) and of those, it was of low/mild intensity in 81% of cases (Figure 1). 
Other  common  side  effects  were  abnormal  dreams  (13.6%),  headache  (12.6%)  and  constipation  
(7.8%).  
Less than 2% of smokers without previous history of psychiatric disease reported low mood or 
clinical  depression.  Varenicline  was  discontinued  in  nine  cases,  one  of  them  due  to  a  depressive 
episode and in eight smokers (3%) due to side effects such as nausea (5/8) and insomnia (3/8). All of 
them were excluded from the analysis. 
 
Figure 1. Percentage of adverse events. N = 103. 
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4. Discussion 
Previous  trials  [10-14]  had  reported  that  varenicline  was  most  effective  than  placebo,  nicotine 
patches and bupropion for smoking cessation. In a recent meta-analysis [15], where data from three 
trials of varenicline with an active bupropion arm was used, varenicline was superior to bupropion with 
an estimated OR of 2.18 (95% CI 1.09-4.08). The present study show data on abstinence after the 
standard period of clinical treatment for smoking cessation with varenicline and cognitive-behavioural 
intervention and, also, defined determinants of success in a clinical context. 
The effectiveness data presented in this study are similar to the results reported in the original 
clinical trials for varenicline. The corresponding real-life effectiveness and continuous abstinence at 12 
weeks  estimated  ranged  from  56.1%  for  males  to  61.5  for  females.  The  week  9-12  continuous 
abstinence rate among our cohort of smokers was 61.3%, comparable with the results reported by 
Aubin et al. (55.9%) [14], but higher than that reported for varenicline group by Jorenby et al. (43.9%) 
[11] and Gonzales et al. (44.0%) [12]. 
Identification  of  individual  characteristics  that  predict  success  in  smoking  cessation  is  highly 
desirable  and  a  number  of  common  predictors  have  been  identified  as  personal,  social  and 
psychopathological factors [16]. Only a study by Stapleton at al. [17] has reported results on predictor 
factors in smoking cessation when varenicline has been used as pharmacological treatment. In our 
study,  age,  other  smokers  in  household,  previous  attempts  and  number  of  cigarettes  emerged  as 
predictors of smoking cessation for the smokers who use varenicline as pharmacological treatment.  
Different studies [16] have shown that age is a determinant of cessation in the general population 
and, a better success rate has always been reported among older smokers. Stalpleton et al. [17] reported 
that age and consumption of cigarettes are prognostic factors for cessation in a cohort who received 
varenicline. Our results suggest that smokers who smoked less than 30 cigarettes per day had higher 
success  rates,  independently  of  other  factors  such  as  FTND  score,  age,  gender  and  previous  quit 
attempts, similar to the data reported by Stapelton et al. [17]. Finally, cohabiting with non-smokers and 
number of previous attempts were also associated with success. 
On  the  other  hand,  the  results  confirm previously data from  clinical  trials that side effects  are 
common during treatment with varenicline although moderate in severity and, in our study, only a 3% 
of smokers need to stop varenicline due to side effects. Although insomnia has been observed more 
frequently than previous studies it could be explained by different reasons than the varenicline use but, 
in general, reported side effects in our study, when vareninline is used in real world setting, are similar 
those observed previously.  
The major limitation of the study is the inclusion of smokers who received expert and behavioural 
support for smoking cessation and observed rates may be different when varenicline could be used as 
pharmacological support in brief counselling and, on the other hand, the absence of a control group 
without behavioural intervention.  
In  conclusion,  varenicline  associated  to  behavioural  intervention  are  effective  for  smoking 
cessation,  when  effectiveness  is  measured  at  the  end  of  treatment  period,  with  high  continuous 
abstinence rates, even more studies with control group without behavioural and using a placebo group 
are needed in the future.  
 Int. J. Environ. Res. Public Health 2009, 6                 
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